Nina Maouelainin, DO, FCCP, MBA
@Lungsolutions
Followers
2K
Following
29K
Media
102
Statuses
10K
Interventional Pulmonologist #WiIP #PhysicianRise #thewhiteribbonproject Founder&President of Lung Health Services/Mother/Speaker/Tweets r my own
Doylestown
Joined June 2011
16
19
95
Data from the Dutch cancer Registry on survival in patients with NSCLC and leptomeningeal metastases @LungCaJournal from @HendriksLizza group. OS with best supportive care 1.3m, with chemo +/- IO ~8m, with targeted therapy 20.5m. Importance of testing. https://t.co/ThDeFHFUN7
lungcancerjournal.info
Leptomeningeal metastases (LM) are a relatively rare but devastating manifestation of metastatic non-small cell lung cancer (NSCLC), occurring when malignant cells spread to the meninges or cerebro...
1
19
37
Such incredible energy from the WiIPs of Brazil! Congratulations on your very first IP event, you absolutely nailed it! Bravo to Bianca, Maria, Viviane, Marcia, and everyone involved, you are truly inspiring!💫 Become a WiIP member: https://t.co/zh0Lawuo3T
#WiPstrong
0
1
2
✨ Happy Diwali!✨ CHEST extends warm wishes to our colleagues, members, and communities celebrating the Festival of Lights. May this season of renewal bring joy, prosperity, and inspiration. #HappyDiwali #FestivalOfLights
0
4
9
A wonderful #ESMO25 with practice changing data - 50 years of progress, 50 years of community with @myESMO, people from around the world unified in a common goal against cancer. #ESMOAmbassadors #myESMOstory
0
7
83
💙Thank you for attending the #SAB session during #CHEST2025 yesterday! It was a privilege to witness the Legends in Pulmonology share their collective expertise, knowledge, and invaluable experiences gained over their impressive careers in the field of #Bronchoscopy! #Educate
0
3
3
Hope. Innovation. Collaboration. In the latest #LungCancerConsidered, @NarjustFlorezMD chats with @nursesteagall & @AmandaNerstad about the 2025 Lung Cancer Hope Summit. Tune in now: https://t.co/N77FyhkSUA
@LUNGevity
0
7
14
A press release summarizes what I thought was the most important lung cancer abstract presented at #ASTRO25. It represents the updated REVISED STARS study results from MDACC. https://t.co/u6wWDW7lvR
1
19
50
Fantastic, thoughtful discussion between @OncBrothers & @lungoncdoc about 1st line treatment options for #EGFR #NSCLC. Having options that have significant OS benefits is amazing, but all regimens have toxicities. Every lung #onc should not just prescribe treatment, but also
In our “Challenging Cases” discussion on metastatic NSCLC mEGFR w/ @lungoncdoc we touch on: ✅ Rx options ✅ AE management ✅ Sequencing Full discussion: ⭐️ https://t.co/XFMkB6kxmY ⭐️ Also on the “Oncology Brothers” podcast #OncTwitter @OncUpdates
3
11
33
Dr. Franziska Trudzinski is passionate about helping mentees sharpen their skills, expand their network, and define their path.💪 Want to apply, but not a member yet? Become a member FIRST: https://t.co/gar0fa2S2p Already or just became a member? Apply: https://t.co/kwoc4SLEh6
0
1
2
🎉 Join the SAB's Membership Committee Member, Dr. Humayun Anjum in Chicago, Illinois during #CHEST2025 TOMORROW - Wednesday, October 19th from 10:45am - 11:00am CDT for, "Beyond the Sputum: Novel Strategies in Bronchiectasis Management – Bronchiectasis Section." #Chicago
0
2
2
Is it possible to identify differential nasopharyngeal aspirate (NPA) biomarkers for the early detection of bronchopulmonary dysplasia (BPD) at 1 week of life? Read the original research in the October issue of the journal CHEST®: https://t.co/DrcnmBppCu
#MedEd #JournalCHEST
0
1
1
Candid interview with my mentee Lina Alami who self challenge of “Ask a question at every session”
0
2
4
Join us for the Chen-Huang Center’s Fifth Annual Patient & Caregiver Forum 🗓 Monday, November 17 | ⏰ 6–8 PM ET | Zoom Join to hear from experts and advocates in the lung cancer community. Register: https://t.co/TF0REtHe7a 📧 Questions? Email- EGFRcenter@dfci.harvard.edu
0
6
10
I’m filled with joy to see my mentor and friend land his 2nd NEJM article after a 20+ year journey defining how to prognosticate PSA relapse and guiding @AstellasUS to design a trial that worked and improved survival. Congrats Steve! @SFreedlandMD
Breaking news from #ESMO25👉Improved OS in high risk biochemical recurrent #ProstateCancer on with ENZA+ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), 👏wonderful news for our pts👉congrats @SFreedlandMD @nealshore & the team. @OncoAlert @urotoday @PCF_Science
1
3
17
#ESMO25 Dr. @MLJohnsonMD2 updates PHAROS: encorafenib + binimetinib in #BRAF V600E NSCLC. 1L RR 75%, DOR 40m (!), PFS 30.4m, OS 47.6m. Later line RR 49%, DOR 16.7m, PFS 9.3m, OS 22.7m. Pyrexia in only 8%, main toxicities nausea, diarrhea. Impressive update! #ESMOAmbassadors
1
22
68
#FLAURA2 for EGFR+ lung cancer Subgroup analysis presented at #ESMO25 Basically every subgroup benefits from combination osi+chemo upfront : baseline CNS, liver Mets, ctDNA+, +TP53 👉🏽The question is who can tolerate it long term ? 🔗Nice to see @NEJM publication out:
nejm.org
The primary analysis of this trial showed that first-line treatment with osimertinib plus chemotherapy with a platinum-based agent and pemetrexed led to significantly longer progression-free surviv...
Pasi Janne presents overall survival by prognostic factors in FLAURA-2 trial of Osimertinib + chemo vs osi alone. Nicely summarized in his last slide. #ESMO25 #LCSM
0
1
9
#ESMO25 Update on Beamion LUNG-1 study of zongertinib, focused on first-line cohort from @DrSanjayPopat. Zongertinib is a HER2 specific, EGFR sparing TKI FDA approved for previously treated #HER2 mutant NSCLC. Here, cohort 2: TKD mutant, treatment naive. #ESMOAmbassadors
1
14
39